{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T03:10:10Z","timestamp":1788318610996,"version":"build-2803163510"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T00:00:00Z","timestamp":1657324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T00:00:00Z","timestamp":1657324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s11926-022-01081-7","type":"journal-article","created":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T07:02:58Z","timestamp":1657350178000},"page":"269-278","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Deep Insight into the Role of MIF in Spondyloarthritis"],"prefix":"10.1007","volume":"24","author":[{"given":"Brian","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4258-1603","authenticated-orcid":false,"given":"Akihiro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,9]]},"reference":[{"key":"1081_CR1","doi-asserted-by":"crossref","unstructured":"Kusuda M, Haroon N, Nakamura A. Complexity of enthesitis and new bone formation in ankylosing spondylitis: current understanding of the immunopathology and therapeutic approaches. Mod Rheumatol. England; 2022;32(3):484-492.","DOI":"10.1093\/mr\/roab057"},{"key":"1081_CR2","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/nrrheum.2017.56","volume":"13","author":"V Ranganathan","year":"2017","unstructured":"Ranganathan V, Gracey E, Brown MA, Inman RD, Haroon N. Pathogenesis of ankylosing spondylitis \u2014 recent advances and future directions. Nat Rev Rheumatol United States. 2017;13:359\u201367.","journal-title":"Nat Rev Rheumatol United States"},{"key":"1081_CR3","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1016\/S0140-6736(11)60071-8","volume":"377","author":"M Dougados","year":"2011","unstructured":"Dougados M, Baeten D. Spondyloarthritis Lancet England. 2011;377:2127\u201337.","journal-title":"Spondyloarthritis Lancet England"},{"key":"1081_CR4","doi-asserted-by":"crossref","unstructured":"Nakamura A, Haroon N. Recent updates in the immunopathology of type 3 immunity-mediated enthesitis. CurrRheumatol Rep. United States; 2021;23:31.","DOI":"10.1007\/s11926-021-00995-y"},{"key":"1081_CR5","volume":"33","author":"A Nakamura","year":"2019","unstructured":"Nakamura A, Talukdar A, Nakamura S, Pathan E, Haroon N. Bone formation in axial spondyloarthritis: is disease modification possible? Best Pract Res Clin Rheumatol. Netherlands. 2019;33: 101491.","journal-title":"Netherlands"},{"key":"1081_CR6","doi-asserted-by":"publisher","first-page":"409","DOI":"10.7326\/M14-2470","volume":"163","author":"NN Haroon","year":"2015","unstructured":"Haroon NN, Paterson JM, Li P, Inman RD, Haroon N. Patients with ankylosing spondylitis have increased cardiovascular and cerebrovascular mortality: a population-based study. Ann Intern Med United States. 2015;163:409\u201316.","journal-title":"Ann Intern Med United States"},{"key":"1081_CR7","doi-asserted-by":"publisher","unstructured":"Kuriya B, Tia V, Luo J, Widdifield J, Vigod S, Haroon N. Acute mental health service use is increased in rheumatoid arthritis and ankylosing spondylitis: a population-based cohort study. Therapeutic Advances in Musculoskeletal Disease [Internet]. SAGE Publications; 2020;12:1759720X20921710. Available from: https:\/\/doi.org\/10.1177\/1759720X20921710","DOI":"10.1177\/1759720X20921710"},{"key":"1081_CR8","doi-asserted-by":"crossref","unstructured":"Deodhar A, Sliwinska-Stanczyk P, Xu H, Baraliakos X, Gensler LS, Fleishaker D, et al. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Annals of the Rheumatic Diseases [Internet]. 2021;80:1004. Available from: http:\/\/ard.bmj.com\/content\/80\/8\/1004.abstract","DOI":"10.1136\/annrheumdis-2020-219601"},{"key":"1081_CR9","doi-asserted-by":"publisher","unstructured":"Genovese MC, Fleischmann R, Combe B, Hall S, Rubbert-Roth A, Zhang Y, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. The Lancet [Internet]. Elsevier; 2018;391:2513\u201324. Available from: https:\/\/doi.org\/10.1016\/S0140-6736(18)31116-4","DOI":"10.1016\/S0140-6736(18)31116-4"},{"key":"1081_CR10","doi-asserted-by":"crossref","unstructured":"Wei JC-C, Kim T-H, Kishimoto M, Ogusu N, Jeong H, Kobayashi S, et al. Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial. Ann Rheum Dis. 2021;","DOI":"10.1136\/annrheumdis-2021-220788"},{"key":"1081_CR11","unstructured":"ClinicalTrials.gov. A study to evaluate the efficacy and safety of bimekizumab in subjects with active nonradiographic axial spondyloarthritis (BE MOBILE 1). 2021."},{"key":"1081_CR12","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1093\/rheumatology\/kez657","volume":"59","author":"GJ Macfarlane","year":"2020","unstructured":"Macfarlane GJ, Pathan E, Jones GT, Dean LE. Predicting response to anti-TNF\u03b1 therapy among patients with axial spondyloarthritis (axSpA): results from BSRBR-AS. Rheumatology (Oxford). 2020;59:2481\u201390.","journal-title":"Rheumatology (Oxford)"},{"key":"1081_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41584-022-00761-z","volume":"18","author":"A Danve","year":"2022","unstructured":"Danve A, Deodhar A. Treatment of axial spondyloarthritis: an update. Nat Rev Rheumatol. 2022;18:205\u201316.","journal-title":"Nat Rev Rheumatol"},{"key":"1081_CR14","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41584-019-0238-2","volume":"15","author":"I Kang","year":"2019","unstructured":"Kang I, Bucala R. The immunobiology of MIF: function, genetics and prospects for precision medicine. Nat Rev Rheumatol United States. 2019;15:427\u201337.","journal-title":"Nat Rev Rheumatol United States"},{"key":"1081_CR15","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1517\/14728220903551304","volume":"14","author":"D Greven","year":"2010","unstructured":"Greven D, Leng L, Bucala R. Autoimmune diseases: MIF as a therapeutic target. Expert Opin Ther Targets England. 2010;14:253\u201364.","journal-title":"Expert Opin Ther Targets England"},{"key":"1081_CR16","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1136\/postgradmedj-2017-134934","volume":"94","author":"S-C Bae","year":"2018","unstructured":"Bae S-C, Lee YH. Associations between circulating macrophage migration inhibitory factor (MIF) levels and rheumatoid arthritis, and between MIF gene polymorphisms and disease susceptibility: a meta-analysis. Postgrad Med J. 2018;94:109\u201315.","journal-title":"Postgrad Med J"},{"key":"1081_CR17","doi-asserted-by":"publisher","first-page":"3942","DOI":"10.1002\/art.30624","volume":"63","author":"A Sreih","year":"2011","unstructured":"Sreih A, Ezzeddine R, Leng L, LaChance A, Yu G, Mizue Y, et al. Dual effect of the macrophage migration inhibitory factor gene on the development and severity of human systemic lupus erythematosus. Arthritis Rheum. 2011;63:3942\u201351.","journal-title":"Arthritis Rheum"},{"key":"1081_CR18","first-page":"927","volume":"34","author":"H-R Kim","year":"2007","unstructured":"Kim H-R, Park M-K, Cho M-L, Yoon C-H, Lee S-H, Park S-H, et al. Macrophage migration inhibitory factor upregulates angiogenic factors and correlates with clinical measures in rheumatoid arthritis. J Rheumatol. 2007;34:927\u201336.","journal-title":"J Rheumatol"},{"key":"1081_CR19","doi-asserted-by":"publisher","unstructured":"Leech M, Lacey D, Xue JR, Santos L, Hutchinson P, Wolvetang E, et al. Regulation of p53 by macrophage migration inhibitory factor in inflammatory arthritis. Arthritis & Rheumatism [Internet]. John Wiley & Sons, Ltd; 2003;48:1881\u20139. Available from: https:\/\/doi.org\/10.1002\/art.11165","DOI":"10.1002\/art.11165"},{"key":"1081_CR20","doi-asserted-by":"crossref","unstructured":"Onodera S, Nishihira J, Iwabuchi K, Koyama Y, Yoshida K, Tanaka S, et al. Macrophage migration inhibitory factor up-regulates matrix metalloproteinase-9 and -13 in rat osteoblasts. Relevance to intracellular signaling pathways. J Biol Chem. 2002;277:7865\u201374.","DOI":"10.1074\/jbc.M106020200"},{"key":"1081_CR21","doi-asserted-by":"publisher","first-page":"5687","DOI":"10.4049\/jimmunol.177.8.5687","volume":"177","author":"AY Hoi","year":"2006","unstructured":"Hoi AY, Hickey MJ, Hall P, Yamana J, O\u2019Sullivan KM, Santos LL, et al. Macrophage migration inhibitory factor deficiency attenuates macrophage recruitment, glomerulonephritis, and lethality in MRL\/lpr mice. J Immunol. 2006;177:5687\u201396.","journal-title":"J Immunol"},{"key":"1081_CR22","doi-asserted-by":"publisher","first-page":"614","DOI":"10.5152\/balkanmedj.2016.141103","volume":"33","author":"\u00c7 G\u00fcrel","year":"2016","unstructured":"G\u00fcrel \u00c7, \u0130nan\u0131r A, Nursal AF, Tekcan A, R\u00fcstemo\u011flu A, Yigit S. Evaluation of MIF -173 G\/C polymorphism in Turkish patients with ankylosing spondylitis. Balkan Med J. 2016;33:614\u20139.","journal-title":"Balkan Med J"},{"key":"1081_CR23","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3109\/s10165-009-0230-9","volume":"20","author":"LD Kozaci","year":"2010","unstructured":"Kozaci LD, Sari I, Alacacioglu A, Akar S, Akkoc N. Evaluation of inflammation and oxidative stress in ankylosing spondylitis: a role for macrophage migration inhibitory factor. Mod Rheumatol. 2010;20:34\u20139.","journal-title":"Mod Rheumatol"},{"issue":"9","key":"1081_CR24","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1002\/art.40175","volume":"69","author":"V Ranganathan","year":"2017","unstructured":"Ranganathan V, Ciccia F, Zeng F, Sari I, Guggino G, Muralitharan J, et al. Macrophage migration inhibitory factor induces inflammation and predicts spinal progression in ankylosing spondylitis. Arthritis and Rheumatology. 2017;69(9):1796\u2013806.","journal-title":"Arthritis and Rheumatology"},{"key":"1081_CR25","doi-asserted-by":"crossref","unstructured":"Nakamura A, Zeng F, Nakamura S, Reid KT, Gracey E, Lim M, et al. Macrophage migration inhibitory factor drives pathology in a mouse model of spondyloarthritis and is associated with human disease. Sci Transl Med. 2021;13:eabg1210.","DOI":"10.1126\/scitranslmed.abg1210"},{"key":"1081_CR26","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.berh.2018.07.004","volume":"31","author":"MA Rahman","year":"2017","unstructured":"Rahman MA, Thomas R. The SKG model of spondyloarthritis. Best Pract Res Clin Rheumatol Netherlands. 2017;31:895\u2013909.","journal-title":"Best Pract Res Clin Rheumatol Netherlands"},{"key":"1081_CR27","first-page":"115","volume":"50","author":"AR Rich","year":"1932","unstructured":"Rich AR, Lewis MR. The nature of allergy in tuberculosis at revealed by tissue culture studies. Bull Johns Hopkins Hosp. 1932;50:115\u201331.","journal-title":"Bull Johns Hopkins Hosp"},{"key":"1081_CR28","doi-asserted-by":"crossref","first-page":"906","DOI":"10.4049\/jimmunol.107.3.906","volume":"107","author":"LS Goldberg","year":"1971","unstructured":"Goldberg LS, Louie JS, Baker MH. Inhibition of macrophage migration: a test system using human monocytes. J Immunol. 1971;107:906\u20139.","journal-title":"J Immunol"},{"key":"1081_CR29","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/nri1200","volume":"3","author":"T Calandra","year":"2003","unstructured":"Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol. 2003;3:791\u2013800.","journal-title":"Nat Rev Immunol"},{"key":"1081_CR30","doi-asserted-by":"publisher","first-page":"E577","DOI":"10.1073\/pnas.1102941108","volume":"108","author":"M Merk","year":"2011","unstructured":"Merk M, Zierow S, Leng L, Das R, Du X, Schulte W, et al. The D-dopachrome tautomerase (DDT) gene product is a cytokine and functional homolog of macrophage migration inhibitory factor (MIF). Proc Natl Acad Sci U S A. 2011;108:E577\u201385.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"23","key":"1081_CR31","doi-asserted-by":"publisher","first-page":"e127171","DOI":"10.1172\/JCI127171","volume":"131","author":"PV Tilstam","year":"2021","unstructured":"Tilstam PV, Schulte W, Holowka T, Kim B-S, Nouws J, Sauler M, et al. MIF but not MIF-2 recruits inflammatory macrophages in an experimental polymicrobial sepsis model. J Clin Invest. 2021;131(23):e127171. https:\/\/doi.org\/10.1172\/JCI127171.","journal-title":"J Clin Invest."},{"key":"1081_CR32","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1002\/art.10492","volume":"46","author":"R Donn","year":"2002","unstructured":"Donn R, Alourfi Z, de Benedetti F, Meazza C, Zeggini E, Lunt M, et al. Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. Arthritis Rheum. 2002;46:2402\u20139.","journal-title":"Arthritis Rheum"},{"key":"1081_CR33","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/art.22179","volume":"54","author":"S-P Wu","year":"2006","unstructured":"Wu S-P, Leng L, Feng Z, Liu N, Zhao H, McDonald C, et al. Macrophage migration inhibitory factor promoter polymorphisms and the clinical expression of scleroderma. Arthritis Rheum. 2006;54:3661\u20139.","journal-title":"Arthritis Rheum"},{"key":"1081_CR34","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.cyto.2012.12.032","volume":"61","author":"MA Llamas-Covarrubias","year":"2013","unstructured":"Llamas-Covarrubias MA, Valle Y, Bucala R, Navarro-Hern\u00e1ndez RE, Palafox-S\u00e1nchez CA, Padilla-Guti\u00e9rrez JR, et al. Macrophage migration inhibitory factor (MIF): genetic evidence for participation in early onset and early stage rheumatoid arthritis. Cytokine. 2013;61:759\u201365.","journal-title":"Cytokine"},{"key":"1081_CR35","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/sj.gene.6363867","volume":"3","author":"JA Baugh","year":"2002","unstructured":"Baugh JA, Chitnis S, Donnelly SC, Monteiro J, Lin X, Plant BJ, et al. A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Genes Immun. 2002;3:170\u20136.","journal-title":"Genes Immun"},{"key":"1081_CR36","doi-asserted-by":"publisher","first-page":"R103","DOI":"10.1186\/ar3828","volume":"14","author":"F-F Wang","year":"2012","unstructured":"Wang F-F, Zhu L-A, Zou Y-Q, Zheng H, Wilson A, Yang C-D, et al. New insights into the role and mechanism of macrophage migration inhibitory factor in steroid-resistant patients with systemic lupus erythematosus. Arthritis Res Ther. 2012;14:R103.","journal-title":"Arthritis Res Ther"},{"key":"1081_CR37","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/rheumatology\/keq102","volume":"49","author":"L Eder","year":"2010","unstructured":"Eder L, Chandran V, Ueng J, Bhella S, Lee K-A, Rahman P, et al. Predictors of response to intra-articular steroid injection in psoriatic arthritis. Rheumatology (Oxford). 2010;49:1367\u201373.","journal-title":"Rheumatology (Oxford)"},{"key":"1081_CR38","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.cellsig.2019.01.006","volume":"57","author":"SS Jankauskas","year":"2019","unstructured":"Jankauskas SS, Wong DWL, Bucala R, Djudjaj S, Boor P. Evolving complexity of MIF signaling. Cell Signal England. 2019;57:76\u201388.","journal-title":"Cell Signal England"},{"key":"1081_CR39","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/nm1567","volume":"13","author":"J Bernhagen","year":"2007","unstructured":"Bernhagen J, Krohn R, Lue H, Gregory JL, Zernecke A, Koenen RR, et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med. 2007;13:587\u201396.","journal-title":"Nat Med"},{"key":"1081_CR40","doi-asserted-by":"publisher","first-page":"19740","DOI":"10.1074\/jbc.RA118.003935","volume":"293","author":"R De","year":"2018","unstructured":"De R, Sarkar S, Mazumder S, Debsharma S, Siddiqui AA, Saha SJ, et al. Macrophage migration inhibitory factor regulates mitochondrial dynamics and cell growth of human cancer cell lines through CD74-NF-\u03baB signaling. J Biol Chem. 2018;293:19740\u201360.","journal-title":"J Biol Chem"},{"key":"1081_CR41","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1006\/cyto.1998.0402","volume":"11","author":"S Onodera","year":"1999","unstructured":"Onodera S, Tanji H, Suzuki K, Kaneda K, Mizue Y, Sagawa A, et al. High expression of macrophage migration inhibitory factor in the synovial tissues of rheumatoid joints. Cytokine. 1999;11:163\u20137.","journal-title":"Cytokine"},{"key":"1081_CR42","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1002\/1529-0131(200201)46:1<232::AID-ART10059>3.0.CO;2-B","volume":"46","author":"C Meazza","year":"2002","unstructured":"Meazza C, Travaglino P, Pignatti P, Magni-Manzoni S, Ravelli A, Martini A, et al. Macrophage migration inhibitory factor in patients with juvenile idiopathic arthritis. Arthritis Rheum. 2002;46:232\u20137.","journal-title":"Arthritis Rheum"},{"key":"1081_CR43","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ni720","volume":"2","author":"YP de Jong","year":"2001","unstructured":"de Jong YP, Abadia-Molina AC, Satoskar AR, Clarke K, Rietdijk ST, Faubion WA, et al. Development of chronic colitis is dependent on the cytokine MIF. Nat Immunol. 2001;2:1061\u20136.","journal-title":"Nat Immunol"},{"key":"1081_CR44","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3109\/s10165-009-0230-9","volume":"20","author":"LD Kozaci","year":"2010","unstructured":"Kozaci LD, Sari I, Alacacioglu A, Akar S, Akkoc N. Evaluation of inflammation and oxidative stress in ankylosing spondylitis: a role for macrophage migration inhibitory factor. Mod Rheumatol. 2010;20:34\u20139.","journal-title":"Mod Rheumatol"},{"issue":"2","key":"1081_CR45","doi-asserted-by":"publisher","first-page":"275","DOI":"10.55563\/clinexprheumatol\/2l5emt","volume":"38","author":"M-C Park","year":"2020","unstructured":"Park M-C, Kwon OC, Lee S-W, Song JJ, Park Y-B. MiR-451 suppresses inflammatory responses in ankylosing spondylitis by targeting macrophage migration inhibitory factor. Clin Exp Rheumatol. 2020;38(2):275\u201381.","journal-title":"Clin Exp Rheumatol."},{"key":"1081_CR46","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1136\/annrheumdis-2012-202208","volume":"73","author":"NT Baerlecken","year":"2014","unstructured":"Baerlecken NT, Nothdorft S, Stummvoll GH, Sieper J, Rudwaleit M, Reuter S, et al. Autoantibodies against CD74 in spondyloarthritis. Ann Rheum Dis England. 2014;73:1211\u20134.","journal-title":"Ann Rheum Dis England"},{"key":"1081_CR47","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1136\/annrheumdis-2012-202177","volume":"73","author":"X Baraliakos","year":"2014","unstructured":"Baraliakos X, Baerlecken N, Witte T, Heldmann F, Braun J. High prevalence of anti-CD74 antibodies specific for the HLA class II-associated invariant chain peptide (CLIP) in patients with axial spondyloarthritis. Ann Rheum Dis England. 2014;73:1079\u201382.","journal-title":"Ann Rheum Dis England"},{"key":"1081_CR48","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/art.40777","volume":"71","author":"E Riechers","year":"2019","unstructured":"Riechers E, Baerlecken N, Baraliakos X, Achilles-Mehr Bakhsh K, Aries P, Bannert B, et al. Sensitivity and specificity of autoantibodies against CD74 in nonradiographic axial spondyloarthritis. Arthritis Rheumatol United States. 2019;71:729\u201335.","journal-title":"Arthritis Rheumatol United States"},{"key":"1081_CR49","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000023433","volume":"99","author":"C-J Hu","year":"2020","unstructured":"Hu C-J, Li M-T, Li X, Peng L-Y, Zhang S-Z, Leng X-M, et al. CD74 auto-antibodies display little clinical value in Chinese Han population with axial spondyloarthritis. Medicine. 2020;99: e23433.","journal-title":"Medicine"},{"key":"1081_CR50","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13075-021-02442-w","volume":"23","author":"M Liu","year":"2021","unstructured":"Liu M, Xie Z, Sun G, Chen L, Qi D, Zhang H, et al. Macrophage migration inhibitory factor may play a protective role in osteoarthritis. Arthritis Res Ther. 2021;23:59.","journal-title":"Arthritis Res Ther"},{"key":"1081_CR51","doi-asserted-by":"crossref","unstructured":"Stoppe C, Averdunk L, Goetzenich A, Soppert J, Marlier A, Kraemer S, et al. The protective role of macrophage migration inhibitory factor in acute kidney injury after cardiac surgery. Sci Transl Med. 2018; 10.aan4886.","DOI":"10.1126\/scitranslmed.aan4886"},{"key":"1081_CR52","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.jbiomech.2010.09.018","volume":"44","author":"S Kitayama","year":"2011","unstructured":"Kitayama S, Onodera S, Kondo E, Kobayashi T, Miyatake S, Kitamura N, et al. Deficiency of macrophage migration inhibitory factor gene delays healing of the medial collateral ligament: a biomechanical and biological study. J Biomech. 2011;44:494\u2013500.","journal-title":"J Biomech"},{"key":"1081_CR53","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nrrheum.2017.188","volume":"13","author":"G Schett","year":"2017","unstructured":"Schett G, Lories RJ, D\u2019Agostino M-A, Elewaut D, Kirkham B, Soriano ER, et al. Enthesitis: from pathophysiology to treatment. Nat Rev Rheumatol United States. 2017;13:731\u201341.","journal-title":"Nat Rev Rheumatol United States"},{"key":"1081_CR54","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nm.2817","volume":"18","author":"JP Sherlock","year":"2012","unstructured":"Sherlock JP, Joyce-Shaikh B, Turner SP, Chao C-C, Sathe M, Grein J, et al. IL-23 induces spondyloarthropathy by acting on ROR-\u03b3t+ CD3+CD4-CD8- entheseal resident T cells. Nat Med United States. 2012;18:1069\u201376.","journal-title":"Nat Med United States"},{"issue":"16","key":"1081_CR55","doi-asserted-by":"publisher","first-page":"8983","DOI":"10.3390\/ijms22168983","volume":"22","author":"D-H Kim","year":"2021","unstructured":"Kim D-H, Noh S-U, Chae S-W, Kim S-J, Lee Y-T. Altered differentiation of tendon-derived stem cells in diabetic conditions mediated by macrophage migration inhibitory factor. Int J Mol Sci. 2021;22(16):8983.","journal-title":"Int J Mol Sci."},{"issue":"11","key":"1081_CR56","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1136\/annrheumdis-2021-220256","volume":"80","author":"M Akbar","year":"2021","unstructured":"\u2022 Akbar M, MacDonald L, Crowe LAN, Carlberg K, Kurowska-Stolarska M, St\u00e5hl PL, et al. Single cell and spatial transcriptomics in human tendon disease indicate dysregulated immune homeostasis. Ann Rheum Dis. 2021;80(11):1494\u20137. This study found tenocyte MIF upregulation in tendinopathy, as well as increase CD74 in macrophages within damaged tendon tissue.","journal-title":"Ann Rheum Dis"},{"key":"1081_CR57","doi-asserted-by":"publisher","first-page":"6196","DOI":"10.1002\/jcp.26475","volume":"233","author":"SJ Kim","year":"2018","unstructured":"Kim SJ, Song D-H, Kim SJ. Characteristics of tendon derived stem cells according to different factors to induce the tendinopathy. J Cell Physiol United States. 2018;233:6196\u2013206.","journal-title":"J Cell Physiol United States"},{"key":"1081_CR58","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/j.1365-2567.2008.02879.x","volume":"126","author":"I Stojanovi\u0107","year":"2009","unstructured":"Stojanovi\u0107 I, Cvjeti\u0107anin T, Lazaroski S, Stosi\u0107-Grujici\u0107 S, Miljkovi\u0107 D. Macrophage migration inhibitory factor stimulates interleukin-17 expression and production in lymph node cells. Immunology. 2009;126:74\u201383.","journal-title":"Immunology"},{"key":"1081_CR59","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.bone.2015.04.035","volume":"80","author":"AD Berendsen","year":"2015","unstructured":"Berendsen AD, Olsen BR. Bone development. Bone. 2015;80:14\u20138.","journal-title":"Bone"},{"key":"1081_CR60","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.12125","volume":"9","author":"Y Zheng","year":"2021","unstructured":"Zheng Y, Cai B, Ren C, Xu H, Du W, Wu Y, et al. Identification of immune related cells and crucial genes in the peripheral blood of ankylosing spondylitis by integrated bioinformatics analysis. PeerJ. 2021;9: e12125.","journal-title":"PeerJ"},{"key":"1081_CR61","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41413-021-00140-6","volume":"9","author":"T Yu","year":"2021","unstructured":"\u2022\u2022 Yu T, Zhang J, Zhu W, Wang X, Bai Y, Feng B, et al. Chondrogenesis mediates progression of ankylosing spondylitis through heterotopic ossification. Bone Res. 2021;9:19. This study firmly shows that endochondral ossification is one of the central process of new bone formation in axSpA.","journal-title":"Bone Res"},{"key":"1081_CR62","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1002\/jcp.26036","volume":"233","author":"Y Fujihara","year":"2018","unstructured":"Fujihara Y, Hikita A, Takato T, Hoshi K. Roles of macrophage migration inhibitory factor in cartilage tissue engineering. J Cell Physiol United States. 2018;233:1490\u20139.","journal-title":"J Cell Physiol United States"},{"key":"1081_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.714011","volume":"9","author":"M Deng","year":"2021","unstructured":"\u2022 Deng M, Tan J, Dai Q, Luo F, Xu J. Macrophage-mediated bone formation in scaffolds modified with MSC-derived extracellular matrix is dependent on the migration inhibitory factor signaling pathway. Front Cell Dev Biol. 2021;9: 714011. This study identified macrophage-derived MIF as a regulatory cytokine in osteogenesis using cartilage implants.","journal-title":"Front Cell Dev Biol"},{"key":"1081_CR64","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.bone.2009.06.028","volume":"45","author":"C Jacquin","year":"2009","unstructured":"Jacquin C, Koczon-Jaremko B, Aguila HL, Leng L, Bucala R, Kuchel GA, et al. Macrophage migration inhibitory factor inhibits osteoclastogenesis. Bone. 2009;45:640\u20139.","journal-title":"Bone"},{"key":"1081_CR65","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1002\/jbmr.1787","volume":"28","author":"SH Mun","year":"2013","unstructured":"Mun SH, Won HY, Hernandez P, Aguila HL, Lee S-K. Deletion of CD74, a putative MIF receptor, in mice enhances osteoclastogenesis and decreases bone mass. J Bone Miner Res. 2013;28:948\u201359.","journal-title":"J Bone Miner Res"},{"key":"1081_CR66","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1359\/jbmr.060310","volume":"21","author":"S Onodera","year":"2006","unstructured":"Onodera S, Sasaki S, Ohshima S, Amizuka N, Li M, Udagawa N, et al. Transgenic mice overexpressing macrophage migration inhibitory factor (MIF) exhibit high-turnover osteoporosis. J Bone Miner Res. 2006;21:876\u201385.","journal-title":"J Bone Miner Res"},{"key":"1081_CR67","doi-asserted-by":"publisher","first-page":"7667","DOI":"10.1096\/fj.201802364RR","volume":"33","author":"L Zheng","year":"2019","unstructured":"Zheng L, Gao J, Jin K, Chen Z, Yu W, Zhu K, et al. Macrophage migration inhibitory factor (MIF) inhibitor 4-IPP suppresses osteoclast formation and promotes osteoblast differentiation through the inhibition of the NF-\u03baB signaling pathway. FASEB J. 2019;33:7667\u201383.","journal-title":"FASEB J"},{"key":"1081_CR68","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s13075-020-02327-4","volume":"22","author":"E Christodoulou-Vafeiadou","year":"2020","unstructured":"Christodoulou-Vafeiadou E, Geka C, Ntari L, Kranidioti K, Argyropoulou E, Meier F, et al. Ectopic bone formation and systemic bone loss in a transmembrane TNF-driven model of human spondyloarthritis. Arthritis Res Ther. 2020;22:232.","journal-title":"Arthritis Res Ther"},{"key":"1081_CR69","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3899\/jrheum.161216","volume":"45","author":"U Kopylov","year":"2018","unstructured":"Kopylov U, Starr M, Watts C, Dionne S, Girardin M, Seidman EG. Detection of Crohn disease in patients with spondyloarthropathy: the SpACE capsule study. J Rheumatol. 2018;45:498\u2013505.","journal-title":"J Rheumatol"},{"issue":"Suppl 2","key":"1081_CR70","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/rheumatology\/XXVII.suppl_2.95","volume":"27","author":"H Mielants","year":"1988","unstructured":"Mielants H, Veys EM, Cuvelier C, de Vos M. Ileocolonoscopic findings in seronegative spondylarthropathies. Br J Rheumatol. 1988;27(Suppl 2):95\u2013105.","journal-title":"Br J Rheumatol"},{"key":"1081_CR71","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1136\/annrheumdis-2012-202135","volume":"72","author":"L van Praet","year":"2013","unstructured":"van Praet L, van den Bosch FE, Jacques P, Carron P, Jans L, Colman R, et al. Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model. Ann Rheum Dis. 2013;72:414\u20137.","journal-title":"Ann Rheum Dis"},{"key":"1081_CR72","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1136\/gut.2006.107649","volume":"56","author":"J Oliver","year":"2007","unstructured":"Oliver J, M\u00e1rquez A, G\u00f3mez-Garcia M, Martinez A, Mendoza JL, Vilchez JR, et al. Association of the macrophage migration inhibitory factor gene polymorphisms with inflammatory bowel disease. Gut. 2007;56:150\u20131.","journal-title":"Gut"},{"key":"1081_CR73","doi-asserted-by":"publisher","first-page":"11392","DOI":"10.3390\/ijms140611392","volume":"14","author":"Y Shen","year":"2013","unstructured":"Shen Y, Guo S, Yang T, Jia L, Chen L, An J, et al. The -173 G\/C polymorphism of the MIF gene and inflammatory bowel disease risk: a meta-analysis. Int J Mol Sci. 2013;14:11392\u2013401.","journal-title":"Int J Mol Sci"},{"key":"1081_CR74","first-page":"9570","volume":"8","author":"J Yang","year":"2015","unstructured":"Yang J, Li Y, Zhang X. Meta-analysis of macrophage migration inhibitory factor (MIF) gene -173G\/C polymorphism and inflammatory bowel disease (IBD) risk. Int J Clin Exp Med. 2015;8:9570\u20134.","journal-title":"Int J Clin Exp Med"},{"key":"1081_CR75","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.cyto.2015.10.008","volume":"77","author":"UP Singh","year":"2016","unstructured":"Singh UP, Singh NP, Murphy EA, Price RL, Fayad R, Nagarkatti M, et al. Chemokine and cytokine levels in inflammatory bowel disease patients. Cytokine. 2016;77:44\u20139.","journal-title":"Cytokine"},{"key":"1081_CR76","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/j.1365-2249.2005.02771.x","volume":"140","author":"T Ohkawara","year":"2005","unstructured":"Ohkawara T, Miyashita K, Nishihira J, Mitsuyama K, Takeda H, Kato M, et al. Transgenic over-expression of macrophage migration inhibitory factor renders mice markedly more susceptible to experimental colitis. Clin Exp Immunol. 2005;140:241\u20138.","journal-title":"Clin Exp Immunol"},{"key":"1081_CR77","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1080\/00365520802273017","volume":"43","author":"T Ohkawara","year":"2008","unstructured":"Ohkawara T, Mitsuyama K, Takeda H, Asaka M, Fujiyama Y, Nishihira J. Lack of macrophage migration inhibitory factor suppresses innate immune response in murine dextran sulfate sodium-induced colitis. Scand J Gastroenterol. 2008;43:1497\u2013504.","journal-title":"Scand J Gastroenterol"},{"key":"1081_CR78","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1053\/gast.2002.34236","volume":"123","author":"T Ohkawara","year":"2002","unstructured":"Ohkawara T, Nishihira J, Takeda H, Hige S, Kato M, Sugiyama T, et al. Amelioration of dextran sulfate sodium-induced colitis by anti-macrophage migration inhibitory factor antibody in mice. Gastroenterology. 2002;123:256\u201370.","journal-title":"Gastroenterology"},{"key":"1081_CR79","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jcmgh.2020.01.009","volume":"10","author":"L Farr","year":"2020","unstructured":"Farr L, Ghosh S, Jiang N, Watanabe K, Parlak M, Bucala R, et al. CD74 Signaling links inflammation to intestinal epithelial cell regeneration and promotes mucosal healing. Cell Mol Gastroenterol Hepatol. 2020;10:101\u201312.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"1081_CR80","doi-asserted-by":"publisher","first-page":"6337","DOI":"10.1038\/s41598-018-24706-3","volume":"8","author":"M Vujicic","year":"2018","unstructured":"Vujicic M, Saksida T, Despotovic S, Bajic SS, Lali\u0107 I, Koprivica I, et al. The role of macrophage migration inhibitory factor in the function of intestinal barrier. Sci Rep. 2018;8:6337.","journal-title":"Sci Rep"},{"key":"1081_CR81","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1136\/annrheumdis-2013-203582","volume":"74","author":"C Stolwijk","year":"2015","unstructured":"Stolwijk C, van Tubergen A, Castillo-Ortiz JD, Boonen A. Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74:65\u201373.","journal-title":"Ann Rheum Dis"},{"key":"1081_CR82","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/BF00372087","volume":"282","author":"RS G\u00f3mez","year":"1990","unstructured":"G\u00f3mez RS, Diepgen TL, Neumann C, Sorg C. Detection of migration inhibitory factor (MIF) by a monoclonal antibody in the microvasculature of inflamed skin. Arch Dermatol Res. 1990;282:374\u20138.","journal-title":"Arch Dermatol Res"},{"key":"1081_CR83","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1046\/j.0022-202x.2001.01366.x","volume":"116","author":"T Shimizu","year":"2001","unstructured":"Shimizu T, Nishihira J, Mizue Y, Nakamura H, Abe R, Watanabe H, et al. High macrophage migration inhibitory factor (MIF) serum levels associated with extended psoriasis. J Invest Dermatol. 2001;116:989\u201390.","journal-title":"J Invest Dermatol"},{"key":"1081_CR84","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1046\/j.1365-2133.1999.03206.x","volume":"141","author":"M Steinhoff","year":"1999","unstructured":"Steinhoff M, Meinhardt A, Steinhoff A, Gemsa D, Bucala R, Bacher M. Evidence for a role of macrophage migration inhibitory factor in psoriatic skin disease. Br J Dermatol. 1999;141:1061\u20136.","journal-title":"Br J Dermatol"},{"key":"1081_CR85","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/j.0022-202X.2004.23314.x","volume":"123","author":"RP Donn","year":"2004","unstructured":"Donn RP, Plant D, Jury F, Richards HL, Worthington J, Ray DW, et al. Macrophage migration inhibitory factor gene polymorphism is associated with psoriasis. J Invest Dermatol. 2004;123:484\u20137.","journal-title":"J Invest Dermatol"},{"key":"1081_CR86","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.3389\/fimmu.2018.02262","volume":"9","author":"S Bezdek","year":"2018","unstructured":"Bezdek S, Leng L, Busch H, Mousavi S, Rades D, Dahlke M, et al. Macrophage migration inhibitory factor (MIF) drives murine Psoriasiform dermatitis. Front Immunol. 2018;9:2262.","journal-title":"Front Immunol"},{"key":"1081_CR87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0925-4439(99)00080-0","volume":"1500","author":"R Abe","year":"2000","unstructured":"Abe R, Shimizu T, Ohkawara A, Nishihira J. Enhancement of macrophage migration inhibitory factor (MIF) expression in injured epidermis and cultured fibroblasts. Biochim Biophys Acta. 2000;1500:1\u20139.","journal-title":"Biochim Biophys Acta"},{"key":"1081_CR88","doi-asserted-by":"publisher","first-page":"3693","DOI":"10.4049\/jimmunol.1400692","volume":"193","author":"C-Y Hsieh","year":"2014","unstructured":"Hsieh C-Y, Chen C-L, Lin Y-S, Yeh T-M, Tsai T-T, Hong M-Y, et al. Macrophage migration inhibitory factor triggers chemotaxis of CD74+CXCR2+ NKT cells in chemically induced IFN-\u03b3-mediated skin inflammation. J Immunol. 2014;193:3693\u2013703.","journal-title":"J Immunol"},{"key":"1081_CR89","first-page":"247","volume":"40","author":"N Kitaichi","year":"1999","unstructured":"Kitaichi N, Kotake S, Sasamoto Y, Namba K, Matsuda A, Ogasawara K, et al. Prominent increase of macrophage migration inhibitory factor in the sera of patients with uveitis. Invest Ophthalmol Vis Sci. 1999;40:247\u201350.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1081_CR90","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1136\/bjo.85.11.1367","volume":"85","author":"C Taguchi","year":"2001","unstructured":"Taguchi C, Sugita S, Tagawa Y, Nishihira J, Mochizuki M. Macrophage migration inhibitory factor in ocular fluids of patients with uveitis. Br J Ophthalmol. 2001;85:1367\u201371.","journal-title":"Br J Ophthalmol"},{"key":"1081_CR91","doi-asserted-by":"publisher","first-page":"7734","DOI":"10.1167\/iovs.13-12187","volume":"54","author":"C Zhang","year":"2013","unstructured":"Zhang C, Liu S, Hou S, Lei B, Zheng X, Xiao X, et al. MIF gene polymorphisms confer susceptibility to Vogt-Koyanagi-Harada syndrome in a Han Chinese population. Invest Ophthalmol Vis Sci. 2013;54:7734\u20138.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1081_CR92","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1159\/000489340","volume":"27","author":"AF Nursal","year":"2018","unstructured":"Nursal AF, Yigit S, Tural E, Kalkan G, Tumer MK, Tekcan A. Macrophage migration inhibitory factor \u2212173GC variant might increase the risk of Beh\u00e7et\u2019s disease. Med Princ Pract. 2018;27:285\u20139.","journal-title":"Med Princ Pract"},{"key":"1081_CR93","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1016\/j.ophtha.2012.06.039","volume":"119","author":"X Zheng","year":"2012","unstructured":"Zheng X, Wang D, Hou S, Zhang C, Lei B, Xiao X, et al. Association of macrophage migration inhibitory factor gene polymorphisms with Beh\u00e7et\u2019s disease in a Han Chinese population. Ophthalmology. 2012;119:2514\u20138.","journal-title":"Ophthalmology"},{"key":"1081_CR94","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/cei.12710","volume":"183","author":"H Yang","year":"2016","unstructured":"Yang H, Zheng S, Mao Y, Chen Z, Zheng C, Li H, et al. Modulating of ocular inflammation with macrophage migration inhibitory factor is associated with notch signalling in experimental autoimmune uveitis. Clin Exp Immunol. 2016;183:280\u201393.","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"1081_CR95","doi-asserted-by":"crossref","first-page":"e13328","DOI":"10.1111\/acel.13328","volume":"20","author":"DE Harrison","year":"2021","unstructured":"Harrison DE, Strong R, Reifsnyder P, Kumar N, Fernandez E, Flurkey K, et al. 17-a-estradiol late in life extends lifespan in aging UM-HET3 male mice; nicotinamide riboside and three other drugs do not affect lifespan in either sex. Aging Cell England. 2021;20(5):e13328.","journal-title":"Aging Cell. England"},{"key":"1081_CR96","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1111\/bcp.14289","volume":"86","author":"D Mahalingam","year":"2020","unstructured":"\u2022\u2022 Mahalingam D, Patel MR, Sachdev JC, Hart LL, Halama N, Ramanathan RK, et al. Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours. Br J Clin Pharmacol. 2020;86:1836\u201348. This trial shows that MIF antagonism yields a desirable safety profile in humans.","journal-title":"Br J Clin Pharmacol"},{"key":"1081_CR97","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1136\/annrheumdis-2020-219803","volume":"80","author":"DJ Wallace","year":"2021","unstructured":"\u2022\u2022 Wallace DJ, Figueras F, Wegener WA, Goldenberg DM. Experience with milatuzumab, an anti-CD74 antibody against immunomodulatory macrophage migration inhibitory factor (MIF) receptor, for systemic lupus erythematosus (SLE). Ann Rheum Dis. 2021;80:954\u20135. This trial shows that monoclonal antibody against CD74 is effective for a sizable proportion of SLE patients and well-tolerable.","journal-title":"Ann Rheum Dis"},{"key":"1081_CR98","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/ni.2921","volume":"15","author":"WM Nauseef","year":"2014","unstructured":"Nauseef WM, Borregaard N. Neutrophils at work. Nat Immunol United States. 2014;15:602\u201311.","journal-title":"Nat Immunol United States"},{"key":"1081_CR99","first-page":"1377","volume":"54","author":"GL Burn","year":"2021","unstructured":"Burn GL, Foti A, Marsman G, Patel DF, Zychlinsky A. The neutrophil Immunity United States. 2021;54:1377\u201391.","journal-title":"The neutrophil Immunity United States"},{"key":"1081_CR100","doi-asserted-by":"publisher","first-page":"105066","DOI":"10.1016\/j.micpath.2021.105066","volume":"158","author":"ZA Tabrizi","year":"2021","unstructured":"Tabrizi ZA, Khosrojerdi A, Aslani S, Hemmatzadeh M, Babaie F, Bairami A, et al. Multi-facets of neutrophil extracellular trap in infectious diseases: moving beyond immunity. Microb Pathog, England. 2021;158:105066.","journal-title":"Microb Pathog, England"},{"key":"1081_CR101","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1136\/ard.44.5.312","volume":"44","author":"AJ Freemont","year":"1985","unstructured":"Freemont AJ, Denton J. Disease distribution of synovial fluid mast cells and cytophagocytic mononuclear cells in inflammatory arthritis. Ann Rheum Dis. 1985;44:312\u20135.","journal-title":"Ann Rheum Dis"},{"key":"1081_CR102","doi-asserted-by":"publisher","first-page":"17514","DOI":"10.1002\/anie.202101864","volume":"60","author":"Z Xiao","year":"2021","unstructured":"Xiao Z, Song S, Chen D, van Merkerk R, van der Wouden PE, Cool RH, et al. Proteolysis targeting chimera (PROTAC) for macrophage migration inhibitory factor (MIF) has anti-proliferative activity in lung cancer cells. Angew Chem Int Ed Engl. 2021;60:17514\u201321.","journal-title":"Angew Chem Int Ed Engl"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-022-01081-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11926-022-01081-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-022-01081-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T11:30:10Z","timestamp":1700825410000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11926-022-01081-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,9]]},"references-count":102,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["1081"],"URL":"https:\/\/doi.org\/10.1007\/s11926-022-01081-7","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,9]]},"assertion":[{"value":"5 June 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}